These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 16868793)

  • 1. Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment.
    Darreh-Shori T; Meurling L; Pettersson T; Hugosson K; Hellström-Lindahl E; Andreasen N; Minthon L; Nordberg A
    J Neural Transm (Vienna); 2006 Nov; 113(11):1791-801. PubMed ID: 16868793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
    Darreh-Shori T; Hosseini SM; Nordberg A
    J Alzheimers Dis; 2014; 39(2):423-40. PubMed ID: 24217282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.
    Nordberg A; Darreh-Shori T; Peskind E; Soininen H; Mousavi M; Eagle G; Lane R
    Curr Alzheimer Res; 2009 Feb; 6(1):4-14. PubMed ID: 19199870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group.
    Rogers SL; Friedhoff LT
    Dementia; 1996; 7(6):293-303. PubMed ID: 8915035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease.
    Davidsson P; Blennow K; Andreasen N; Eriksson B; Minthon L; Hesse C
    Neurosci Lett; 2001 Mar; 300(3):157-60. PubMed ID: 11226635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
    Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina.
    Amici S; Lanari A; Romani R; Antognelli C; Gallai V; Parnetti L
    Mech Ageing Dev; 2001 Nov; 122(16):2057-62. PubMed ID: 11589922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease.
    Kaasinen V; Någren K; Järvenpää T; Roivainen A; Yu M; Oikonen V; Kurki T; Rinne JO
    J Clin Psychopharmacol; 2002 Dec; 22(6):615-20. PubMed ID: 12454562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation of plasma IC50 of donepezil for cerebral acetylcholinesterase inhibition in patients with Alzheimer disease using positron emission tomography.
    Ota T; Shinotoh H; Fukushi K; Kikuchi T; Sato K; Tanaka N; Shimada H; Hirano S; Miyoshi M; Arai H; Suhara T; Irie T
    Clin Neuropharmacol; 2010; 33(2):74-8. PubMed ID: 19935404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid acetylcholinesterase changes after treatment with donepezil in patients with Alzheimer's disease.
    García-Ayllón MS; Silveyra MX; Andreasen N; Brimijoin S; Blennow K; Sáez-Valero J
    J Neurochem; 2007 Jun; 101(6):1701-11. PubMed ID: 17326766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The measured CSF/plasma donepezil concentration ratio but not individually measured CSF and plasma concentrations significantly increase over 24 h after donepezil treatment in patients with Alzheimer's disease.
    Valis M; Dlabkova A; Hort J; Angelucci F; Pejchal J; Kuca K; Pavelek Z; Karasova JZ; Novotny M
    Biomed Pharmacother; 2023 Mar; 159():114223. PubMed ID: 36630846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine.
    Darreh-Shori T; Kadir A; Almkvist O; Grut M; Wall A; Blomquist G; Eriksson B; Långström B; Nordberg A
    Neurobiol Aging; 2008 Feb; 29(2):168-84. PubMed ID: 17196712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease.
    Bohnen NI; Kaufer DI; Hendrickson R; Ivanco LS; Lopresti BJ; Koeppe RA; Meltzer CC; Constantine G; Davis JG; Mathis CA; Dekosky ST; Moore RY
    J Neurol Neurosurg Psychiatry; 2005 Mar; 76(3):315-9. PubMed ID: 15716518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
    Parnetti L; Amici S; Lanari A; Romani C; Antognelli C; Andreasen N; Minthon L; Davidsson P; Pottel H; Blennow K; Gallai V
    Neurol Sci; 2002 Sep; 23 Suppl 2():S95-6. PubMed ID: 12548360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease.
    Parnetti L; Chiasserini D; Andreasson U; Ohlson M; Hüls C; Zetterberg H; Minthon L; Wallin AK; Andreasen N; Talesa VN; Blennow K
    Acta Neurol Scand; 2011 Aug; 124(2):122-9. PubMed ID: 20880294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors.
    Nobili F; Koulibaly M; Vitali P; Migneco O; Mariani G; Ebmeier K; Pupi A; Robert PH; Rodriguez G; Darcourt J
    J Nucl Med; 2002 Aug; 43(8):983-90. PubMed ID: 12163621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concentration of Donepezil in the Cerebrospinal Fluid of AD Patients: Evaluation of Dosage Sufficiency in Standard Treatment Strategy.
    Valis M; Masopust J; Vysata O; Hort J; Dolezal R; Tomek J; Misik J; Kuca K; Karasova JZ
    Neurotox Res; 2017 Jan; 31(1):162-168. PubMed ID: 27718143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive stimulation therapy for Alzheimer's disease: the effect of cognitive stimulation therapy on the progression of mild Alzheimer's disease in patients treated with donepezil.
    Matsuda O
    Int Psychogeriatr; 2007 Apr; 19(2):241-52. PubMed ID: 17005066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex.
    Kuhl DE; Minoshima S; Frey KA; Foster NL; Kilbourn MR; Koeppe RA
    Ann Neurol; 2000 Sep; 48(3):391-5. PubMed ID: 10976649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.